RNAi News and Research

RSS

Labcyte awarded 2nd Japanese patent for acoustic-based cell sorting system

Labcyte, the company that developed and commercialized the acoustic transfer of liquids today announced that the Japanese patent office has granted patent 4309131 that covers the design of an acoustic-based system that can sort cells based upon acoustic or other properties and then eject them specifically from a mixed population.

18 Aug 2009

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam Pharmaceuticals, Inc. and Tekmira Pharmaceuticals Corporation announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.

6 Aug 2009

Identification of cholesterol regulating genes by targeted RNAi-screening

Scientists at the European Molecular Biology Laboratory (EMBL) and the University of Heidelberg, Germany, have come a step closer to understanding how cholesterol levels are regulated. In a study published today in the journal Cell Metabolism, the researchers identified 20 genes that are involved in this process. Besides giving scientists a better idea of where to look to uncover the mechanisms that ensure cholesterol balance is maintained, the discovery could lead to new treatments for cholesterol-related diseases.

7 Jul 2009

'Trojan horse' cancer therapy beats tumours resistant to chemotherapy

A new therapy to treat cancer has been developed by Australian scientists and it promises to have far fewer unpleasant side effects than conventional treatments and should also be much cheaper.

28 Jun 2009

Intradigm issued RNA interference (RNAi) patent covering potent siRNA sequence

Intradigm Corporation has announced the issuance of United States patent 7,534,878, titled "Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases."

19 May 2009

New system to deliver siRNA into primary cells

In technology that promises to one day allow drug delivery to be tailored to an individual patient and a particular cancer tumor, researchers at the University of California, San Diego School of Medicine, have developed an efficient system for delivering siRNA into primary cells.

17 May 2009

Oral delivery system for RNAi therapeutics

Researchers at the University of Massachusetts Medical School (UMMS) report on a novel approach to the delivery of small bits of genetic material in order to silence genes using "RNA interference"-and in the process, discovered a potent method of suppressing inflammation in mice similar to what occurs in a range of human diseases.

30 Apr 2009

Welcome news on Dengue fever

The news that scientists in the United States have identified host factors which are critical to Dengue virus infection will be particularly welcome in tropical northern Queensland, which has suffered one of the worse Dengue fever outbreaks in decades.

26 Apr 2009

Scientists identify dozens of proteins the dengue fever virus depends upon

By painstakingly silencing genes one at a time, scientists at Duke University Medical Center have identified dozens of proteins the dengue fever virus depends upon to grow and spread among mosquitoes and humans.

22 Apr 2009

New Dengue virus discovery could lead to development of anti-dengue drugs

Doctors have no specific drugs to treat dengue fever, a viral illness spread by mosquitoes that sickens 50 million to 100 million people worldwide each year. Instead, the only treatments they can recommend for this painful and sometimes fatal illness (20,000 deaths globally each year) are fluids, rest and non-aspirin pain and fever reducers.

22 Apr 2009

Discovery of key decision-point at which cells with broken DNA repair themselves or die

When cells undergo potentially catastrophic damage, for example as a result of exposure to ionizing radiation, they must make a decision: either to fix the damage or program themselves for death, a process called apoptosis.

12 Apr 2009

Researchers explain process by which cells 'hide' potentially dangerous DNA segments

The DNA in the 23 pairs of chromosomes in each of the billions of cells of the human body is so tightly packed that it would measure six feet in length if stretched end to end.

12 Apr 2009

Intradigm receives notice of allowance for key RNA interference patent covering potent siRNA sequence

Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, has announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance for a patent covering various aspects of a potent small interfering RNA (siRNA) sequence.

17 Mar 2009

Protein function and chromatin structure methods featured in Cold Spring Harbor Protocols

Two new methods for analyzing the roles played by proteins in cells are featured in the March issue of Cold Spring Harbor Protocols.

3 Mar 2009

Novel gene silencing platform

A team of researchers led by Rutgers' Samuel Gunderson has developed a novel gene silencing platform with very significant improvements over existing RNAi approaches.

16 Feb 2009

Novel gene silencing platform

A team of researchers led by Rutgers' Samuel Gunderson has developed a novel gene silencing platform with very significant improvements over existing RNAi approaches.

8 Feb 2009

Topical treatment wipes out herpes with RNAi

Whether condoms or abstinence, most efforts to prevent sexually transmitted diseases have a common logic: keep the pathogen out of your body altogether.

21 Jan 2009

Topical microbicide protects against genital herpes

A topical microbicide that silences two genes can safely protect against genital herpes infection for as long as one week, according to a joint study by researchers at the Albert Einstein College of Medicine of Yeshiva University and Harvard Medical School.

21 Jan 2009

Liquidia Technologies to collaborate with Abbott on siRNA therapeutics

Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

7 Jan 2009

Blocking mechanism found for antibiotic resistance in bacteria

It's as simple as A, T, G, C. Northwestern University scientists have exploited the Watson-Crick base pairing of DNA to provide a defensive tool that could be used to fight the spread of antibiotic resistance in bacteria -- one of the world's most pressing public health problems.

18 Dec 2008